

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to the Acceptance of a Subsidiary’s Drug Registration Application” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

8 April 2024

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to the Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement, or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein contained.

I. Overview

Recently, new drugs applications of Deferasirox Granules and Deferasirox Tablets (the “**New Drugs**”) independently researched and developed by Fosun Pharmaceutical Industrial Development Company Limited* (上海醫藥產業發展有限公司), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥 (集團) 股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”), have been accepted by the National Medical Products Administration.

II. General information and research progress of the New Drugs

The New Drugs are chemical drugs independently developed by the Group, intended to be used for (1) treatment of chronic iron overload due to blood transfusion (transfusional iron overload), (2) treatment of chronic iron overload in non-transfusion-dependent thalassemia syndromes.

As of February 2024, the Group has invested approximately RMB7.92 million and RMB11.30 million (unaudited) in total in the research and development of the Deferasirox Granule and Deferasirox Tablets at current stage, respectively.

As at the date of this announcement, the deferasirox preparations which have been

approved to be launched in China (excluding Hong Kong, Macau, and Taiwan region for the purpose of this announcement, the same applies below) mainly include Exjade[®] (Deferasirox Dispersible Tablets) of Novartis Pharma Stein AG, Aofaluo(奧法羅)[®] (Deferasirox Dispersible Tablets) of Jiangsu Aosaikang Pharmaceutical Co., Ltd.*(江蘇奧賽康藥業有限公司) and Deferasirox Tablets of Jiangsu Hansoh Pharmaceutical Group Co., Ltd.* (江蘇豪森藥業集團有限公司). According to the latest data of IQVIA CHPA¹, the sales of the deferasirox preparations in China in 2022 was approximately RMB120 million.

III. Risk Warning

The New Drugs are subject to, among others, the passing of the GMP compliance inspection and the drug registration approval before commercial production. These acceptance of the drug registration application will not have a material impact on the results of the Group at this stage.

Due to the industry characteristics of pharmaceutical products, the specific sales performance after the market launch of pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, etc., and is subject to considerable uncertainty. Investors should take note of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

8 April 2024

** For identification purposes only*

¹ Data provided by IQVIA, a provider of professional medical and health information and strategic consultation service in the world; IQVIA CHPA data covers the drug sales market of hospitals with more than 100 beds in China, the actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales channels.